169209-63-6 Usage
Uses
(2R,4R)-APDC is a potent and selective group II metabotropic glutamate receptor agonist (1,2). It has been shown that (2R,4R)-APDC decrease cell proliferation in the dentate gyrus of adult rats (1).
Biological Activity
A highly selective and relatively potent group II metabotropic glutamate receptor agonist. EC 50 values are 0.4, 0.4, > 100, > 100, > 300 and > 300 μ M for human mGlu 2 , mGlu 3 , mGlu 1 , mGlu 5 , mGlu 4 and mGlu 7 receptors respectively. Centrally active following systemic administration in vivo . Also available as part of the Group II mGlu Receptor Tocriset? .
in vitro
2r,4r-apdc blocked forskolin-stimulated camp with none of the other activities of ls,3r-acpd. forskolin-stimulated camp formation in human mglur2 expressing cells with about three-fold greater potency than ls,3r-acpd were also inhibited by 2r,4r-apdc, which, unlike ls,3r-acpd, exhibited no appreciable activation of phosphoinostide hydrolysis in human mglur. thus, 2r,4r-apdc should be a useful pharmacological tool to explore the functions of mglurs coupled to inhibition of adenylate cyclase [1]. the effects of four isomers of apdc were investigated at glutamate receptors in vitro. (2r,4r)-apdc, an aza analog of the nonselective mglur agonist (1s,3r)-acpd possessed relatively high affinity for metabotropic glutamate receptors (mglurs) with no effects on radioligand binding to nmda, ampa, or kainate receptors up to 100 ím. none of the other apdc isomers exhibited significant mglur binding affinity, indicating that this interaction is highly stereospecific [2].
in vivo
both (1s,3r)-acpd and (2r,4r)-apdc were effectively attenuating forskolin-stimulated camp formation in the adult rat cerebral cortex; however, while (1s,3r)-acpd was also effectively stimulating basal tritiated inositol monophosphate production of the neonatal rat cerebral cortex, (2r,4r)-apdc was not effectively stimulating phosphoinositide hydrolysis in this tissue preparation. an augmentation of ampa-induced excitation was produced by microelectrophoretic application of either (1s,3r)-acpd or (2r,4r)-apdc to intact rat spinal neurons [2].
references
[1] schoepp dd, johnson bg, salhoff cr, valli mj, desai ma, burnett jp, mayne ng, monn ja. selective inhibition of forskolin-stimulated cyclic amp formation in rat hippocampus by a novel mglur agonist, 2r,4r-4-aminopyrrolidine-2,4- dicarboxylate. neuropharmacology. 1995 aug;34(8):843-50.[2] monn ja, valli mj, johnson bg, salhoff cr, wright ra, howe t, bond a, lodge d, spangle la, paschal jw, campbell jb, griffey k, tizzano jp, schoepp dd. synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. j med chem. 1996 jul 19; 39 (15):2990-3000.
Check Digit Verification of cas no
The CAS Registry Mumber 169209-63-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,2,0 and 9 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 169209-63:
(8*1)+(7*6)+(6*9)+(5*2)+(4*0)+(3*9)+(2*6)+(1*3)=156
156 % 10 = 6
So 169209-63-6 is a valid CAS Registry Number.
169209-63-6Relevant articles and documents
Synthesis, molecular modeling, and biology of the 1-benzyl derivative of APDC - an apparent mGluR6 selective ligand
Tueckmantel, Werner,Kozikowski, Alan P.,Wang, Shaomeng,Pshenichkin, Sergey,Wroblewski, Jarda T.
, p. 601 - 606 (2007/10/03)
The synthesis of the 1-benzyl derivative of (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylic acid (1-benzyl-APDC) starting from cis-4-hydroxy-D-proline is disclosed together with a study of the activity of this compound at metabotropic glutamate receptors (mGl
PYRROLIDINYL DI-CARBOXYLIC ACID DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS
-
, (2008/06/13)
The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
